Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a biopharmaceutical company focused on rare hematology diseases and rare diseases of the immune system, with a core emphasis on CXCR4‑targeted therapies. Its news flow frequently centers on the development and commercialization of mavorixafor, an orally available CXCR4 antagonist marketed in the United States as XOLREMDI® in its first indication and under active investigation in chronic neutropenia and other rare hematologic conditions.
On this page, readers can review news items that X4 has issued about its clinical, corporate and financial milestones. These include updates on the global, pivotal Phase 3 4WARD trial in chronic neutropenia, where mavorixafor is being evaluated as an oral, once‑daily therapy with or without G‑CSF in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who experience recurrent and serious infections. News coverage also highlights Phase 2 trial data demonstrating durable increases in absolute neutrophil count, reductions or discontinuation of injectable G‑CSF in many participants, and safety observations consistent with previous mavorixafor studies.
Investors and observers will also find press releases on financing transactions such as private placements of common stock and pre‑funded warrants, underwritten public offerings, and an equity purchase agreement with Lincoln Park Capital Fund, LLC. These announcements describe how X4 intends to fund the pivotal development of mavorixafor in chronic neutropenia and support its commercialization activities. Additional news items cover organizational restructuring, workforce reductions, leadership and board changes, and participation in healthcare and hematology conferences where X4 presents clinical data and corporate updates.
By following XFOR news, readers can track how X4 Pharmaceuticals reports progress in its rare hematology programs, interprets emerging clinical results for mavorixafor, and manages its capital structure and operations as it advances its CXCR4‑based therapeutic strategy.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to host a virtual seminar titled “Understanding Primary Immunodeficiencies” on December 16, 2021, at 8:30 a.m. EST. The seminar aims to showcase new clinical data on mavorixafor, their leading candidate for treating immunodeficiencies, particularly in the context of WHIM syndrome. Esteemed guest speakers include experts such as Neal Sondheimer, M.D., and Theresa Tarrant, M.D. The event will also highlight relevant research from the upcoming ASH Annual Meeting. A live webcast will be available on the company's website.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced on December 1, 2021, that its Compensation Committee granted inducement awards to new employees. These awards include options for 17,000 shares and restricted stock units for 25,000 shares under the 2019 Inducement Equity Incentive Plan. The options have a ten-year term with an exercise price of $4.45 per share, vesting over four years. X4 focuses on developing CXCR4-targeted therapies, notably mavorixafor, which is undergoing clinical trials for various immune system diseases.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 11:20 AM ET. The event will feature a fireside chat, which will be available via live webcast on X4's investor website. X4 is focused on developing novel CXCR4-targeted therapies for immune system diseases, with mavorixafor as its lead candidate. The company is advancing mavorixafor through various clinical trials for conditions including primary immunodeficiencies and certain cancers. The archived event will be accessible for 90 days post-conference.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) reported significant advancements in its WHIM syndrome treatment, mavorixafor, including the completion of enrollment in a pivotal Phase 3 trial. The company anticipates top-line data in Q4 2022. Recent findings indicate a potential U.S. WHIM patient population of 3,700, with mavorixafor demonstrating increased neutrophil levels and good tolerability. Financial results show a net loss of $20.2 million for Q3 2021, up from $17.4 million year-over-year. An Investor Day is scheduled for December 16, highlighting further clinical data.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on November 1, 2021, that its Compensation Committee granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The awards include options to purchase 11,050 shares of common stock at an exercise price of $4.84 per share, matching the stock's closing price on October 29, 2021. Options vest over four years, with a quarter vesting after one year. X4 focuses on CXCR4-targeted therapies for immune system diseases, with its lead candidate mavorixafor currently undergoing multiple clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its upcoming earnings call on November 4, 2021, at 9:05 a.m. ET. The call will cover the third quarter financial results and recent business highlights. Additionally, the company is expected to discuss abstracts accepted for the 63rd American Society of Hematology (ASH) Annual Meeting, with publication set for the same day at 9:00 a.m. ET. X4 is focused on developing mavorixafor, a novel CXCR4-targeted therapy, currently undergoing clinical trials for various rare diseases.
X4 Pharmaceuticals has appointed Françoise de Craecker to its Board of Directors and hired Karolyn Park as Vice President, U.S. Commercial. These strategic moves aim to enhance the company's leadership as it prepares for the anticipated U.S. launch of its lead candidate, mavorixafor. De Craecker brings over 30 years of experience in launching rare disease products globally, while Park has nearly 20 years in life science marketing. The hiring is viewed as a critical step in maximizing mavorixafor's potential to treat immunodeficiencies and cancers.
X4 Pharmaceuticals (Nasdaq: XFOR) has completed enrollment in its pivotal Phase 3 trial for mavorixafor, targeting WHIM syndrome, with 31 patients enrolled, surpassing the original goal of 18-28. Top-line data is expected in Q4 2022, followed by a potential U.S. NDA filing in Q1 2023. WHIM syndrome is a rare primary immunodeficiency caused by mutations in the CXCR4 gene. Mavorixafor has received various designations from the FDA, highlighting its therapeutic potential in immunodeficiencies.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on September 30, 2021, the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards comprise options to purchase 95,200 shares and restricted stock units covering 6,000 shares of common stock. The exercise price for options is set at $5.29 per share, matching the closing price on the grant date. Options will vest over four years, while restricted stock units will vest annually over the same period, contingent upon continued employment.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 11:35 a.m. ET. Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 30, 2021, at 10:00 a.m. ET. Live webcasts of both events will be accessible through the investors section of X4 Pharmaceuticals' website and will be archived for 90 days. X4 is focused on developing therapies for diseases linked to the CXCR4 pathway.